Aids in management of patients with bladder cancer patients in conjunction with cystoscopy. Qualitative assay detects bladder tumor-associated antigen in urine of patients diagnosed with bladder cancer.
New York DOH Approval Status
Voided urine or urine from a catheterized patient.
Transfer 2 mL urine to an ARUP Standard Transport Tube.
Do not use paper or foam cups for urine specimen collection or storage.
Ambient: 48 hours; Refrigerated: 1 week; Frozen: 6 months
Positive: Bladder tumor associated antigen detected.
Negative: Bladder tumor associated antigen not detected.
Results of this test should not be interpreted as absolute evidence of the presence or absence of bladder cancer. Any disease that would cause endogenous human complement factor H (hCFH) to leak into the bladder can cause a positive test result. Positive results have been associated with renal stones, nephritis, renal cancer (including upper tract TCC), urinary tract infections, cystitis, sexually transmitted diseases and recent trauma to the bladder or urinary tract. This test should not be used as a screening test for individuals without biopsy-confirmed bladder cancer. The result from the BTA stat test should be used only in conjunction with information available from the clinical evaluation of the patient and other diagnostic procedures.
|Component Test Code*||Component Chart Name||LOINC|
|8100523||Bladder Tumor Antigen Specimen Source||31208-2|
- Bladder Cancer
- Bladder Tumor
- Bladder Tumor Antigen
- Urinary Tract Cancer
- Urothelial Carcinoma